Granules Pharma Receives USFDA EIR for Chantilly Facility with VAI Classification
Granules Pharmaceuticals, Inc., a subsidiary of Granules India Limited, has received an Establishment Inspection Report (EIR) from the USFDA for its Chantilly, Virginia facility. The facility received a Voluntary Action Indicated (VAI) classification. The inspection took place from March 30 to April 3, 2026, with four Form 483 observations issued.
Receiving a VAI classification from the USFDA is a positive development for a manufacturing facility, ensuring its continued operation within the critical US market. However, the issuance of 483 observations suggests areas for improvement, moderating the impact to medium.
The company received a Voluntary Action Indicated (VAI) classification from the USFDA, which is generally viewed positively as it indicates no major compliance issues requiring immediate corrective action beyond the observations made.
Granules India Limited announced on June 3, 2026, that its wholly-owned subsidiary, Granules Pharmaceuticals, Inc. (GPI), located in Chantilly, Virginia, US, has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA). The classification for the facility is Voluntary Action Indicated (VAI).
The USFDA inspection for the Chantilly facility was conducted from March 30 to April 3, 2026. During this inspection, four Form 483 observations were issued.
This facility is noted as playing an important role in Granules' global manufacturing and supply network. The company emphasizes its continued focus on quality systems, regulatory compliance, and patient safety at this site. Granules reiterates its commitment to maintaining the highest standards of quality, safety, and regulatory compliance across all its manufacturing facilities in India and the US.
What to do with a filing like this
Granules India Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Granules India Limited. Read the original for the full detail.